A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACTOR X in the Treatment of Factor X Deficient Subjects Undergoing Surgery

Trial Profile

A Phase III Open, Multicentre Study to Investigate the Safety and Efficacy of BPL's High Purity FACTOR X in the Treatment of Factor X Deficient Subjects Undergoing Surgery

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Factor X (Primary)
  • Indications Factor X deficiency
  • Focus Registrational; Therapeutic Use
  • Sponsors Bio Products Laboratory
  • Most Recent Events

    • 30 Mar 2016 Results published in Bio Products media release.
    • 30 Mar 2016 According to Bio Products media release, European Medicines Agency has granted marketing authorisation for Coagadex.
    • 21 Oct 2015 According to a Bio Products Laboratory media release, the US FDA had approved Coagadex for the treatment of adults and children (aged 12 years and over) with hereditary factor X deficiency.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top